Anti-CD19 CAR T cells for refractory myasthenia gravis
- PMID: 37977704
- DOI: 10.1016/S1474-4422(23)00375-7
Anti-CD19 CAR T cells for refractory myasthenia gravis
Conflict of interest statement
DB is an employee and shareholder of Kyverna Therapeutics. GS has received consulting fees from Kyverna Therapeutics and Cabaletta. All other authors declare no competing interests. AH and TH contributed equally. DM provided the pivotal conceptual framework of the study. AH and DM have verified the data presented; all authors had full access to all the data analysed in the case report and accept responsibility for submitting this Correspondence for publication. The study was supported by the Deutsche Forschungsgemeinschaft (FOR2886, RTG2408, TRR221, CRC1181).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical